BioMarin Pharmaceutical Inc. (BMRN) Institutional Ownership & Insider Trading

563 institutions reported holding BioMarin Pharmaceutical Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 5 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BMRNBioMarin Pharmaceutical Inc.Follow BMRN — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 10.8B
P/E TTM: 151.2
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 10 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

563 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +2.4%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	563	196	+2.4%	177	68	175	63
Mar 26	550	184	+0.9%	192	63	145	57
Dec 25	530	188	+0.4%	157	67	202	108
Sep 25	562	180	-1.1%	199	51	182	55
Jun 25	573	185	+0.5%	219	65	168	68
Mar 25	570	179	+0.4%	209	74	157	47
Dec 24	526	183	-0.2%	180	47	171	80
Sep 24	539	177	-3.4%	176	69	176	72

BioMarin Pharmaceutical Inc. — questions

Who owns BioMarin Pharmaceutical Inc. stock?: 563 institutions reported BioMarin Pharmaceutical Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (10.6%), Dodge & Cox (7.7%), PRIMECAP MANAGEMENT CO/CA/ (7.3%).
Are BioMarin Pharmaceutical Inc. insiders buying or selling?: 5 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from BioMarin Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.